2,3 11 Beta-Prostaglandin F2 Alpha Prostaglandin Mastocytosis 23BPG 11BPG BPG2 11 Beta-Prostaglandin F2 Alpha
Screening for mast cell activation disorders including systemic mastocytosis
For 24-hour Urine Collection:
1. Collect urine for 24 hours.
2. Refrigerate specimen during collection, and send specimen refrigerated.
For Random Urine Collection:
1. Collect a random urine specimen.
2. Refrigerate specimen after collection. Send specimen refrigerated or frozen; do not add any preservative.
Patient Preparation: Patients taking aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) may have decreased concentrations of prostaglandin F2 alpha. If possible, discontinue for 2 weeks or 72 hours, respectively, prior to collecting a specimen.
Elevated levels of 2,3-dinor-11beta-prostaglandin F2 alpha (2,3 BPG) in urine are not specific for systemic mast cell disease and may be found in patients with angioedema, diffuse urticaria, or myeloproliferative diseases in the absence of diffuse mast cell proliferation.
Systemic mast cell disease is a heterogeneous disease, and some patients may not have elevated (2,3 BPG) in urine.
23BPG: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
AACT: Enzymatic Colorimetric Assay
Urinary 2,3-dinor-11beta-prostaglandin F2 alpha (2,3-BPG) values above 3,263 pg/mg creatinine are consistent with, but not necessarily diagnostic of, systemic mastocytosis. Values should be interpreted in the context of clinical presentation and additional mast cell disease markers (serum tryptase, urinary N-methyl histamine, and/or urinary leukotriene E4).